上海醫藥(02607.HK)子公司艾司唑侖片通過仿製藥一致性評價 2021-05-20T09:18:07-04:00May 20th, 2021| share this article! 【財華社訊】上海醫藥(02607.HK)公布,公司控股子公司山東信誼製藥有限公司收到國家藥品監督管理局頒發的關於艾司唑侖片的《藥品補充申請批准通知書》(通知書編號:2021B01316),該藥品通過仿製藥質量和療效一致性評價。艾司唑侖片主要用於抗焦慮、失眠或緊張、恐懼及抗癲癇和抗驚厥。 Read More share this article! Related Posts India: Wipro COO Amit Choudhary quits, business head Jain to take over May 17th, 2024 Haidilao restaurant operator Super Hi surges 46% on U.S. listing debut May 17th, 2024 Goldman Sachs to double down on PE credit lines as dealmaking picks up May 17th, 2024 India’s education-focused fintech Propelld raises $25m for NBFC unit Edgro May 17th, 2024